Somatostatin Receptor Splicing Variant sst5TMD4 Overexpression in Glioblastoma Is Associated with Poor Survival, Increased Aggressiveness Features, and Somatostatin Analogs Resistance

Antonio C. Fuentes-Fayos(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Raúl M. Luque(Instituto de Salud Carlos III), Alejandro Ibáñez‐Costa(Instituto de Salud Carlos III), Cristóbal Blanco-Acevedo(Instituto Maimónides de Investigación Biomédica de Córdoba), Justo P. Castaño(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Miguel E. G-García(Instituto Maimónides de Investigación Biomédica de Córdoba), Jesús M. Pérez‐Gómez(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition), Annabel Peel(Cardiff University), Juan Solivera(Instituto Maimónides de Investigación Biomédica de Córdoba), Manuel D. Gahete(Spanish Biomedical Research Centre in Physiopathology of Obesity and Nutrition)
International Journal of Molecular Sciences
January 20, 2022
10.3390/ijms23031143
Cited by 9

Related Papers

THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: G protein‐coupled receptors
|British Journal of Pharmacology|2021|488
The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptors
|British Journal of Pharmacology|2023|390
International Union of Basic and Clinical Pharmacology. CV. Somatostatin Receptors: Structure, Function, Ligands, and New Nomenclature
|Pharmacological Reviews|2018|251
Splicing machinery dysregulation drives glioblastoma development/aggressiveness: oncogenic role of SRSF3
|Brain|2020|103
Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas
|Cancer Letters|2015|91